Recently stock market analysts have updated their consensus ratings on shares of Allergan, Inc. (NYSE:AGN).

Most recent broker ratings

04/27/2016 – Allergan, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 300 price target on the stock.

04/18/2016 – Goldman Sachs began new coverage on Allergan, Inc. giving the company a “buy” rating. They now have a USD 275 price target on the stock.

04/18/2016 – Guggenheim began new coverage on Allergan, Inc. giving the company a “neutral” rating.

04/18/2016 – Allergan, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 238 price target on the stock.

04/07/2016 – Allergan, Inc. had its “overweight” rating reiterated by analysts at Morgan Stanley. They now have a USD 300 price target on the stock.

04/07/2016 – Allergan, Inc. had its “neutral” rating reiterated by analysts at Susquehanna. They now have a USD 275 price target on the stock.

04/07/2016 – Allergan, Inc. had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 275 price target on the stock.

04/07/2016 – Allergan, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 325 price target on the stock.

04/07/2016 – Allergan, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 285 price target on the stock.

04/06/2016 – Allergan, Inc. had its “buy” rating reiterated by analysts at Nomura. They now have a USD 330 price target on the stock.

04/06/2016 – Allergan, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 272 price target on the stock.

04/06/2016 – Allergan, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 282 price target on the stock.

04/06/2016 – Allergan, Inc. was downgraded to “neutral” by analysts at Mizuho. They now have a USD 250 price target on the stock.

04/05/2016 – Allergan, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 354 price target on the stock.

03/31/2016 – Allergan, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 320 price target on the stock.

Allergan, Inc. has a 50 day moving average of 239.23 and a 200 day moving average of 281.47. The stock’s market capitalization is 79.59B, it has a 52-week low of 195.50 and a 52-week high of 340.34.

The share price of the company (NYSE:AGN) was down -4.13%, with a high of 209.08 during the day and the volume of Allergan, Inc. shares traded was 12808590.

View other investors thoughts on Allergan, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.